Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Ixyldone 40 mg prolonged-release tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Oxycodone hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Oxycodone hydrochloride

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Ixyldone is a strong acting painkiller (analgesic) and belongs to the group of opioids. Ixyldone is used to treat severe pain, which can be adequately managed only with opioid analgesics. Ixyldone is indicated in adults and adolescents aged 12 years and older. 2.

What you need to know before you take it

e Ixyldone

Do not take Ixyldone

  • if you are allergic to oxycodone hydrochloride or any of the other ingredients of this medicine (listed in section 6),
  • if your breathing is not sufficient; that means significantly shallow or slowed down (severe respiratory depression)
  • if you suffer from severe chronic obstructive lung disease associated with obstruction of the airways (COPD)
  • if you suffer from cor pulmonale (heart problems after long term lung disease)
  • if you suffer from severe bronchial asthama
  • if you suffer from intestinal paralysis, a condition in which the intestine has stopped working (paralytic ileus) Warnings and precautions Talk to your doctor or pharmacist before taking Ixyldone
  • if you are older or debilitated,
  • if you have severe lung problem
  • if your liver or kidney function is impaired
  • if you have a thyroid disease where the skin on the face and limbs is pasty, swollen, cool and dry,
  • if your thyroid produces an insufficient amount of hormones (called underactive thyroid or

1

• • • • • • • • • • • • • • • • •

hypothyroidism) if you have Addison's disease if you have enlarged prostate gland, which causes difficulty in passing urine if you suffer with psychosis caused by alcohol or have a mental disorder as a result of an infection (toxic psychosis) if you are an alcoholic if you are or have ever been addicted to alcohol or drugs, or have a known opioid-dependence if you have or had a dependency on strong painkillers (opioids) if you have inflammation of the pancreas (which causes severe pain in the abdomen and back), problems with your gall bladder or bile duct if you have colicky abdominal pain or discomfort if you have an obstructive or inflammatory bowel disorder if your doctor suspects that you have intestinal paralysis (a condition where your bowel has stopped working) if you have a severe headache or feel sick as this may indicate that the pressure in your skull is increased if you suffer from disturbances of circulatory regulation if you suffer from epilepsy or have a seizure tendency if you take medicines for the treatment of depression (MAO inhibitors), e.g. tranylcypromine, phenelzine, isocarboxazid, moclobemide or linezolid, or you have taken this type of medicine in the last two weeks if you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction") if you are a smoker if you have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses

Do not use for short-term post-operative pain owing to the increased risk of dependence and breathlessness If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are taking Ixyldone. Your doctor may adjust your dose.

Contact your doctor if you experience severe upper abdominal pain possibly radiating to the back, nausea, vomiting or fever as this could be symptoms associated with inflammation of the pancreas (pancreatitis) and the biliary tract system. Tolerance, dependence and addiction This medicine contains oxycodone, which is an opioid. It can cause dependence and/or addiction. This medicine contains oxycodone which is an opioid medicine. Repeated use of opioid painkillers can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Ixyldone may lead to dependence, abuse and addiction, which may result in lifethreatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent or addicted on Ixyldone if:

2

  • You or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction").
  • You are a smoker.
  • You have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking Ixyldone, it could be a sign that you have become dependent or addicted.
  • You need to take the medicine for longer than advised by your doctor
  • You need to take more than the recommended dose
  • You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'
  • You have made repeated, unsuccessful attempts to quit or control the use of the medicine
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects') If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (See section 3, If you stop taking Ixyldone). Sleep-related breathing disorders Ixyldone can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Talk to your doctor if any of these conditions apply to you. The most significant risk of overdose of opioids is slow and shallow breathing (respiratory depression). This is most likely to occur in elderly and debilitated patients and may also cause a drop in blood pressure. This could lead to e.g. fainting. This medicine has been specially formulated to release the active substance over a 12-hour period. Ixyldone prolonged-release tablets are not allowed to be divided, chewed or crushed. This would lead to a potentially lethal dose of the active substance oxycodone hydrochloride (see under "If you take more Ixyldone tablets than you should or if someone accidentally swallows your tablets"). When used for a long time (chronic) tolerance to the effects may appear and you may require progressively higher doses of Ixyldone to maintain pain control. Do not change the dosage without consulting your doctor. For pain not related to cancer, opioids are not the drug of first choice and are not recommended as the only treatment. Other medicines should be used together with opioids in the treatment of chronic pain. Your doctor should monitor you closely and make any necessary adjustments to your dose while you are taking Ixyldone to prevent addiction and abuse. Prolonged use of Ixyldone may lead to physical dependence. If treatment is stopped abruptly, withdrawal symptoms may occur such as yawning, abnormal dilation of the pupils, tear disorder, runny nose, shaking, sweating, anxiety, convulsions, difficulty sleeping or muscle pain. When you no longer require therapy with Ixyldone, it may be advisable for your doctor to taper the dose gradually. The active substance oxycodone hydrochloride, similar to other strong opioids (strong painkillers) has a primary dependence potential.

3

Developing psychological dependence may be possible. In cases of present or past abuse of alcohol or medicines, Ixyldone must be used with special caution only. Especially in high dosages you may experience increased sensitivity to pain (hyperalgesia) despite the fact that you are taking increasing doses of Ixyldone. Your doctor will decide whether you need a change in dose or a change in strong analgesic (opioids). Ixyldone are for oral use only (swallowing of whole tablets). The prolonged release tablets should not be dissolved and injected, as this can cause serious, possibly fatal consequences. If you are going to have an operation, please tell the doctor at the hospital that you are taking Ixyldone. Similar to other opioids, oxycodone can affect the normal production of the body's hormones (such as cortisol or sex hormones). This happens especially if you have received high doses over long periods of time. You may see the residue of the tablet in your stool. Do not worry, as the active substance oxycodone has been released earlier while the tablet passed through the gastric system and has started to be effective in your body. Children (under 12 years of age) Safety and efficacy have not been established in children under 12 years of age. Therefore, Ixyldone is not recommended in children under 12 years of age. Anti-doping warning The use of Ixyldone may lead to positive results in doping controls. Use of Ixyldone as a doping agent may become a health hazard. Other medicines and Ixyldone Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. Use of opioids including Ixyldone and sedative medicines such as benzodiazepines or related drugs together increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe Ixyldone together with sedative medicines, the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Side effects of Ixyldone may occur more frequent or more severe if you use Ixyldone concomitantly with medicines that may interfere with the brain function or are used to treat allergies, motion sickness or vomiting. Side effects may occur e.g. flattening and slowing down of breathing (respiratory depression), constipation, dry mouth or disorders in urination. The risk of side effects increases if you use antidepressants (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine). These medicines may interact with oxycodone and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, and body temperature above 38°C. Contact your doctor when experiencing such symptoms. Please tell your doctor or pharmacist if you are taking any of the following medicines:

  • medicines to help you sleep or stay calm (for example tranquillisers, hypnotics or sedatives including benzodiazepines)
  • medicines to treat depression (for example paroxetine or amitriptyline) including those medicines belonging to the group of MAO-inhibitors (such as tranylcypromine,

4

• • • • • • • • • • • • • • •

phenelzine, isocarboxazid, moclobemide or linezolid) medicines for allergies, motion sickness or vomiting (antihistamines, antiemetics) medicines to treat psychiatric or mental disorders (such as psychotropic drugs, phenothiazines or neuroleptic drugs) medicines for the treatment of epilepsy, pain and anxiety, such as gabapentin and pregabalin muscle relaxants for the treatment of muscle cramps (such as tizanidine) medicines to treat Parkinson's disease other strong acting painkillers (opioids) cimetidine (a medicine for stomach ulcers, indigestion or heartburn) medicines to treat fungal infections (such as ketoconazole, voriconazole, itraconazole, or posaconazole) medicines used to treat infections (such as clarithromycin, erythromycin or telithromycin) medicines from the group of protease inhibitors to treat HIV (such as boceprevir, ritonavir, indinavir, nelfinavir or saquinavir) rifampicin to treat tuberculosis carbamazepine (a medicine to treat epilepsy or seizures, and certain pain conditions) phenytoin (a medicine to treat seizures, fits or convulsions) the medical plant St John's Wort (also known as Hypericum perforatum) quinidine (medicine to treat cardiac arrhythmias) certain medicines to prevent your blood clotting or to help thin your blood (e.g. phenprocoumon)

Ixyldone with food, drink and alcohol Drinking alcohol whilst taking Ixyldone may make you feel more sleepy and increase the risk of serious side effects such as shallow breathing with a risk of stopping breathing, and loss of consciousness. It is recommended not to drink alcohol while you are taking Ixyldone. While taking Ixyldone you should avoid drinking grapefruit juice. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy You should not use Ixyldone if you are pregnant. There are limited data from the use of oxycodone in humans during pregnancy. Prolonged use of oxycodone during pregnancy can cause withdrawal symptoms in the newborn. Use of oxycodone during childbirth can cause shallow and slowed down breathing (respiratory depression) in your newborn. Breast-feeding You should not take Ixyldone if you are breast-feeding as the active substance oxycodone may pass in the breast milk and cause sedation and shallow and slowed down breathing (respiratory depression) in the breast-fed child. Driving and using machines Ixyldone may impair the ability to drive or operate machinery. This is particularly likely at the beginning of therapy with Ixyldone, after increasing the dose, after a change of the medicinal preparation as well as the interaction of Ixyldone with alcohol or medicinal products which may impair brain function. These tablets may cause a number of side effects such as drowsiness which could affect your ability to drive or use machinery (see section 4 for a full list of side effects). These are usually most noticeable when you first start taking the tablets, or when changing to a higher dose. If you are affected you should not drive or use machinery.

5

The medicine can affect your ability to drive as it may make you sleepy or dizzy.

  • Do not drive while taking this medicine until you know how it affects you.
  • It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').
  • This defence applies when: o The medicine has been prescribed to treat a medical or dental problem and o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine o Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected). Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law. Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Ixyldone contains lactose These tablets contain lactose which is a form of sugar. If you have been told by your doctor that you have an intolerance to some sugars contact your doctor before taking Ixyldone. 3.

How to take it

Ixyldone

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using Ixyldone, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also if you stop taking Ixyldone). Dosage Your doctor will determine how much Ixyldone you should take and how the total daily dose should be divided. Your doctor will adjust the dose to the intensity of the pain and to your individual sensitivity. Do not change the dosage without consulting your doctor. You should receive the lowest effective dose sufficient to relieve your pain. If you have been treated with opioids before, it may be possible that your doctor may start treatment at higher doses. A gradual increase of the dose may be necessary if pain relief is insufficient or the pain level increases. Please talk to you doctor if you suffer from intermittent pain (breakthrough pain) despite pain therapy. Your doctor may prescribe you an additional analgesic (non-sustained analgesic) to treat breakthrough pain or adjust your dosage with Ixyldone. Ixyldone is not intended for the treatment of breakthrough pain. Adults and adolescents (12 years of age and older) Ixyldone prolonged release tablets are available in 5 mg, 10 mg, 15 mg, 20 mg, 30 mg 40 mg, 60 mg and 80 mg strengths. The usual initial dose is 10 mg oxycodone hydrochloride in 12 hourly intervals. For the treatment of non cancer pain a daily dose of 40 mg of oxycodone hydrochloride is generally a sufficient daily dose, but higher dosages may be necessary. Patients with cancer pain usually require dosages from 80 to 120 mg of oxycodone hydrochloride which may be increased up to 400 mg in individual cases.

6

Some patients taking Ixyldone on a fixed schedule require fast-release painkillers as an ondemand medication to manage breakthrough pain. Ixyldone prolonged-release tablets are not intended for the treatment of this breakthrough pain. Elderly patients In elderly patients without liver or kidney problems, dosage adjustment is usually not necessary. Patients with liver or kidney problems If you suffer from liver or kidney problems and you have not received opioids before, you should receive an initial dose of half of the recommended adult dose. Other risk patients If your body weight is low or you have a slower metabolisation rate, and have not taken opioids before, you should initially receive half of the recommended adult dose. Method of administration Oral use Swallow the prolonged-release tablet whole with a sufficient amount of liquid (1⁄2 glass of water) with or without food in the morning and in the evening following a fixed schedule (e.g. at 8 a.m. and 8 p.m.). You can take Ixyldone with or without food. Swallow the prolonged-release tablets as a whole, so that the special prolonged release properties are not affected over a longer period of time. The prolonged-release tablets must be swallowed whole and must not be broken, divided, chewed or crushed. Opening instructions: This medicinal product is in childproof packaging. The prolonged-release tablets cannot be pressed out of the blister. Please observe the following instructions when opening the blister.

1. 2. 3.

Pull off a single dose by tearing along the perforated line on the blister. An unsealed area is exposed/can be reached by this; this area is at the point where the perforated lines intersect with each other. At the unsealed flap, peel away the cover foil from the bottom foil.

Duration of use Your doctor will tell you how long you should take Ixyldone. Do not stop taking Ixyldone without consulting your doctor (see 'if you stop taking Ixyldone'). If you are taking Ixyldone for a long period of time, your treatment should be monitored and discussed

7

regularly with your doctor. This is necessary in order to achieve the best pain therapy possible as well as to be able to treat any occurring side effects, to allow a decision on dose adjustment and to decide whether treatment should be continued. If you feel that the effect of Ixyldone is too strong or too weak, talk to your doctor or pharmacist. If you take more Ixyldone than you should or someone accidentally swallows your tablets If you have taken more Ixyldone than prescribed or someone else has accidentally swallowed your tablets, you should inform your doctor immediately.

Overdose may cause:

  • narrowed pupils (miosis),
  • flattening and slowing down of breathing (respiratory depression),
  • somnolence progressing up to stupor (anaesthesia like condition),
  • decreased tension of skeletal muscles,
  • slowed pulse rate,
  • drop in blood pressure
  • a brain disorder (known as toxic leukoencephalopathy) Loss of consciousness (coma), water retention in the lung and circulatory collapse may occur in more severe cases and may lead to death. Never engage in situations which require a high degree of concentration such as driving. If you forget to take Ixyldone If you use a smaller dose of Ixyldone than prescribed or you miss the intake of a dose, this may result in insufficient pain relief. You can make up for a forgotten dose if the next regular intake is not due for at least another 8 hours. If the time to the next dose is shorter, take the missed dose and take the next dose 8 hours later. You can then continue to take this medicine as directed. In principle, you should not take Ixyldone more than once every 8 hours. Please ask your doctor or pharmacist if you are not sure. Never take a doubled amount of a single dose. If you stop taking Ixyldone Do not stop treatment without informing your doctor. If you stop taking Ixyldone it may lead to withdrawal symptoms (e.g. yawning, dilated pupils, lacrimation, runny nose, tremors, sweating, anxiety, agitation, seizures, insomnia or muscular pains). Therefore, it may be advisable that your doctor gradually reduces the dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. As with other strong analgesics or painkillers, there is a risk that you may become addicted to Ixyldone. If you experience any of the following significant side effects listed below, stop taking Ixyldone and contact your doctor immediately. •

Suddenly occurring breathing problems, swelling of the eyelids, face or lips, rash and itching, especially on the whole body – these are signs of severe allergic reactions.

•

Slow and depressed breathing (respiratory depression) – this mainly occurs if you are older and debilitated or if you have taken too much Ixyldone.

8

•

Severe drop in blood pressure – this may lead to dizziness and fainting (syncope).

•

Narrowing of the pupils, cramping of the bronchial muscles (leads to breathlessness) or depression of the cough reflex.

Other possible side effects Very common (may affect more than 1 in 10 people):

  • constipation – this side effect can be counteracted by preventative measures (such as increased drinking, nutrition rich in fibre)
  • vomiting, nausea – especially at the start of treatment. If you experience nausea or vomiting, your doctor may prescribe medication for you
  • tiredness to drowsiness (sedation)
  • dizziness
  • headache. Common (may affect up to 1 in 10 people):
  • pain
  • diarrhoea
  • dry mouth
  • hiccups
  • indigestion
  • decreased
  • appetite up to loss of appetite
  • altered mood and personality
  • confusion
  • depression
  • decreased activity
  • restlessness
  • increased activity
  • nervousness
  • difficulty in sleeping
  • abnormal thinking
  • muscle tremors
  • lethargy
  • skin reactions/rash
  • sweating
  • pain in urination
  • increased urge to urinate
  • a feeling of unusual weakness, tiredness or fatigue
  • anxiety
  • shortness of breath
  • abdominal pain or discomfort Uncommon (may affect up to 1 in 100 people):
  • withdrawal symptoms
  • need to take higher doses of Ixyldone to achieve the desired pain relief (tolerance development)
  • injuries from accidents
  • allergic reactions (hypersensitivity)
  • loss of body water (dehydration)
  • hyperexcitability, mood swings, a feeling of extreme happiness
  • perception disturbances (e.g. hallucinations, derealisation)

9

• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •

decreased sexual drive epileptic convulsions (especially in people with epilepsy or a tendency to seizures) loss of memory, concentration impaired, migraine increased muscle tension involuntary muscle contractions numbness abnormal coordination difficulty in speaking tingling of skin taste disorder visual impairment hearing impaired a feeling of dizziness or 'spinning' a fast heartbeat, palpitations enlarged blood vessels vocal changes (dysphonia) cough oral ulcers inflammation of the oral mucosa difficulty in swallowing wind belching intestinal paralysis (a condition where the bowel does not work properly increased hepatic enzymes dry skin inability to fully empty the bladder (urinary retention) erectile disorder decreased concentration of sex hormones affecting the sperm production in men or cycle of menstrual period in women chills pain (e.g. chest pain) malaise water retention (oedema, e.g. in hands, ankles or legs, especially at the ankles) thirst.

Rare (may affect up to 1 in 1,000 people):

  • feeling of faintness, especially on standing up
  • dark coloured or tarry stools
  • dental changes
  • bleeding gums
  • infections such as cold sores or herpes (which may cause blisters around the mouth or genitals)
  • increased appetite
  • hives (urticaria)
  • weight increase or decrease. Frequency not known (frequency cannot be estimated from the available data)
  • aggression,
  • increased sensibility to pain
  • dental caries,
  • biliary stasis,
  • biliary colic,
  • absence of menstrual bleeding

10

• • •

withdrawal symptoms in new-borns whose mother used Ixyldone during pregnancy sleep apnoea (breathing pauses during sleep) a problem affecting a valve in the intestines that may cause severe upper abdominal pain (sphincter of Oddi dysfunction)

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Ixyldone

Keep this medicine out of the sight and reach of children. Store this medicine in a locked safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Do not use this medicine after the expiry date which is stated on the blister and the carton after "EXP". The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Content of the pack and other information

What Ixyldone contains The active substance is oxycodone hydrochloride. 15 mg: Each prolonged-release tablet contains 15 mg oxycodone hydrochloride corresponding to 13.5 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, talc, macrogol 400, titanium dioxide (E171), iron oxide black (E172). 20 mg: Each prolonged-release tablet contains 20 mg oxycodone hydrochloride corresponding to 17.9 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, talc, macrogol 400, titanium dioxide (E171), iron oxide red (E172). 30 mg: Each prolonged-release tablet contains 30 mg oxycodone hydrochloride corresponding to 26.9 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, talc, macrogol 400, titanium dioxide (E171), iron oxide brown (E172), iron oxide black (E172).

11

40 mg: Each prolonged-release tablet contains 40 mg oxycodone hydrochloride corresponding to 35.9 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, talc, macrogol 400, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172).

60 mg: Each prolonged-release tablet contains 60 mg oxycodone hydrochloride corresponding to 53.8 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, talc, macrogol 400, titanium dioxide (E171), iron oxide red (E172), erythrosine (E127). 80 mg: Each prolonged-release tablet contains 80 mg oxycodone hydrochloride corresponding to 71.7 mg oxycodone. The other ingredients are: Tablet core: Lactose monohydrate, ammonio methacrylate copolymer Type B dispersion 30%, povidone (K29/32), talc, triacetin, stearyl alcohol, magnesium stearate. Tablet coating: Hypromellose, macrogol 400, titanium dioxide (E171), indigo carmine aluminum lake (E132), iron oxide yellow (E172). What Ixyldone looks like and contents of the pack Ixyldone 15 mg prolonged-release tablets: Grey, round, biconvex, prolonged-release tablets with a diameter of 6.9 – 7.3 mm and a height of 3.2 3.9 mm. Ixyldone 20 mg prolonged-release tablets: Light pink, round, biconvex, prolonged-release tablets with a diameter of 6.9 – 7.3 mm and a height of 3.2 -3.9 mm. Ixyldone 30 mg prolonged-release tablets: Brown, round, biconvex, prolonged-release tablets with a diameter of 6.9 – 7.3 mm and a height of 3.2 -3.9 mm. Ixyldone 40 mg prolonged-release tablets: Light orange to ochre, round, biconvex, prolonged-release tablets with a diameter of 6.9 – 7.3 mm and a height of 3.2 -3.9 mm. Ixyldone 60 mg prolonged-release tablets: Pink-red, round, biconvex, prolonged-release tablets with a diameter of 8.6 – 9.0 mm and a height of 4.6 -5.3 mm. Ixyldone 80 mg prolonged-release tablets: Green, round, biconvex, prolonged-release tablets with a diameter of 8.6 – 9.0 mm and a height of 5.0

  • 5.6 mm. Ixyldone is available for 10, 14, 20, 25, 28, 30, 40, 50, 56, 60, 98 and 100 prolonged-release tablets.

12

Not all pack sizes may be marketed. Marketing Authorisation Holder Morningside Healthcare Ltd. Unit C, Harcourt Way, Leicester LE19 1WP, UK

Manufacturer Acino AG Leopoldstraße 115, 80804 München, Germany [email protected] This leaflet was last revised in December 2024.

13

Frequently asked questions about Ixyldone 40 mg prolonged-release tablets

How do I take Ixyldone 40 mg prolonged-release tablets?

Ixyldone 40 mg prolonged-release tablets comes as tablet containing 40mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Ixyldone 40 mg prolonged-release tablets?

The active substance in Ixyldone 40 mg prolonged-release tablets is oxycodone hydrochloride.

Are there equivalent medicines to Ixyldone 40 mg prolonged-release tablets?

Medicines with the same active substance, strength and form include: Longtec 40 mg Prolonged Release Tablets, Onexila XL 40mg prolonged-release tablets, Oxeltra 40 mg Prolonged-Release Tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Ixyldone 40 mg prolonged-release tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Ixyldone 40 mg prolonged-release tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Oxycodone hydrochloride (89 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Severe pain, which can be sufficiently managed only with opioid analgesics. Ixyldone is indicated in adults and adolescents aged 12 years and older.

4.2. Posology and method of administration

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with oxycodone hydrochloride in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

The dosage depends on the intensity of pain and the patient's individual susceptibility. to the treatment. The following general dosage recommendations apply:

Adults and adolescents 12 years of age and older

Dose titration and adjustment

In general, the initial dose for opioid naïve patients is 10 mg oxycodone hydrochloride given at intervals of 12 hours.

Some patients may benefit from a starting dose of 5 mg oxycodone hydrochloride to minimize the incidence of adverse reactions.

Patients already receiving opioids may start treatment with higher dosages taking into account their experience with former opioid therapies.

For doses not realisable/practicable with this strength other strengths of this medicinal product are available.

According to well-controlled clinical studies 10-13 mg oxycodone ¬hydrochloride correspond to approximately 20 mg morphine sulphate, both in the prolonged-release formulation.

Because of individual differences in sensitivity for different opioids, it is recommended that patients should start conservatively with Ixyldone after conversion from other opioids, with 50-75% of the calculated oxycodone dose.

Some patients who take Ixyldone following a fixed schedule need rapid release analgesics as rescue medication in order to control breakthrough pain. Ixyldone is not indicated for the treatment of acute pain and/or breakthrough pain. The single dose of the rescue medication should amount to 1/6 of the equianalgesic daily dose of Ixyldone. Use of the rescue medication more than twice daily indicates that the dose of Ixyldone needs to be increased. The dose should not be adjusted more often than once every 1-2 days until a stable twice daily administration has been achieved.

Following a dose increase from 10 mg to 20 mg taken every 12 hours dose adjustments should be made in steps of approximately one third of the daily dose. The aim is a patient-specific dosage which, with twice daily administration, allows for adequate analgesia with tolerable undesirable effects and as little rescue medication as possible as long as pain therapy is needed.

Even distribution (the same dose mornings and evenings) following a fixed schedule (every 12 hours) is appropriate for the majority of the patients. For some patients it may be advantageous to distribute the doses unevenly. In general, the lowest effective analgesic dose should be chosen.

For the treatment of non-malignant pain a daily dose of 40 mg is generally sufficient; but higher dosages may be necessary. Patients with cancer-related pain may require dosages of 80 to 120 mg, which in individual cases can be increased to up to 400 mg. If even higher doses are required, the dose should be decided individually balancing efficacy with the tolerance and risk of undesirable effects.

Elderly patients

Elderly patients without clinical manifestation of impaired liver and/or kidney function usually do not require dose adjustments.

Risk patients

Risk patients, for example patients with low body weight or slow metabolism of medicinal products, should initially half the recommended adult dose if they are opioid naïve.

Therefore, the lowest recommended dosage, i.e. 10 mg, may not be suitable as a starting dose.

Dose titration should be performed in accordance with the individual clinical situation.

Patients with renal or hepatic impairment

The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation.

Children under 12 years of age

Oxycodone has not been studied in children younger than 12 years of age. The safety and efficacy of Ixyldone have not been demonstrated and the use in children younger than 12 years of age is therefore not recommended.

Method of administration

For oral use.

Ixyldone should be taken twice daily based on a fixed schedule at the dosage determined.

The prolonged-release tablets may be taken with or independent of meals with a sufficient amount of liquid. Ixyldone must be swallowed whole, not chewed, divided or crushed. Taking chewed, divided or crushed Ixyldone tablets may lead to a rapid release and absorption of a potentially fatal dose of oxycodone.

Ixyldone should not be taken with alcoholic beverages.

Treatment goals and discontinuation

Before initiating treatment with Ixyldone, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with oxycodone, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

Duration of treatment

Ixyldone should not be taken longer than necessary.

If opioid therapy is no longer indicated, it may be advisable to reduce the daily dose gradually in order to prevent symptoms of a withdrawal syndrome.

4.3. Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Severe respiratory depression with hypoxia and/or hypercapnia.

• Severe chronic obstructive pulmonary disease.

• Cor pulmonale.

• Severe bronchial asthma.

• Paralytic ileus.

4.4. Special warnings and precautions for use

Respiratory depression is the most significant risk induced by opioids.

Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI).

Caution must be exercised when administering oxycodone to elderly debilitated patients, in patients with severe impairment of pulmonary function, impaired hepatic or renal function, patients with myxoedema, hypothyroidism, Addison's disease, prostatic hypertrophy, toxic psychosis, alcoholism, delirium tremens, known opioid dependence, disease of the biliary tract, pancreatitis, obstructive and inflammatory bowel disorders, head injuries (due to risk of increased intracranial pressure), hypotension, hypovolemia, epileptic disorder or predisposition to convulsions or patients taking benzodiazepines, or other CNS depressant (including alcohol) or MAO inhibitors.

With the occurrence or suspicion of paralytic ileus, oxycodone should be discontinued immediately.

Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:

Concomitant use of opioids including oxycodone and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Ixyldone concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

To avoid damage to the controlled release properties of the tablets the prolonged release tablets must be swallowed as a whole, not be chewed, divided or crushed. The administration of divided, chewed or crushed tablets leads to a rapid release and absorption of a potentially fatal dose of oxycodone (see section 4.9).

Long-term use of Ixyldone may cause the development of tolerance which leads to the use of higher doses in order to achieve the desired analgesic effect. Prolonged use of Ixyldone may lead to physical dependence. Withdrawal symptoms may occur following abrupt discontinuation of therapy. If therapy with oxycodone is no longer required, it may be advisable to reduce the daily dose gradually in order to avoid the occurrence of withdrawal syndrome.

Withdrawal symptoms may include yawning, mydriasis, lacrimation, rhinorrhoea, tremor, hyperhidrosis, anxiety, agitation, convulsions, insomnia or myalgia.

Opioids, similar to other strong analgesics, are not the first-line treatment for chronic noncancer pain, nor are they recommended as the only treatment. Opioids should be used as part of a comprehensive treatment program that includes other drugs and treatment modalities. Patients with chronic non- cancer related pain should be monitored for addiction development and abuse. In accordance with the pain guidelines, regular reviews should be made to ensure that treatment goals are being achieved, adjust dosage as necessary and decide on continuation or discontinuation of therapy. The dosage has to be adjusted if necessary and a decision has to be taken on the continuation or termination of therapy.

Concomitant use of alcohol and Ixyldone may increase the undesirable effects of Ixyldone; concomitant use should be avoided.

Hyperalgesia that will not respond to a further dose increase of oxycodone may very rarely occur, particularly in high doses. An oxycodone dose reduction or change to an alternative opioid may be required.

Ixyldone should not be used in children younger than 12 years of age because of safety and efficacy concerns.

Ixyldone is not recommended for pre-operative use or within the first 12 – 24 hours post operatively. Depending on the type and extent of the surgical procedure, the selected anaesthetic procedure, the other concomitant medication and the patient's individual condition, the timing of the postoperative use of Ixyldone must be determined after careful consideration of the benefit and risk in each individual case.

Opioids, such as oxycodone hydrochloride, may influence the hypothalamic- pituitary-adrenal or gonadal axes. Some changes that can be seen include an increase in serum prolactin, and a decrease in plasma cortisol and testosterone. Clinical symptoms may manifest from these hormonal changes.

Like all opioid containing preparations, Ixyldone should be used with caution in patients undergoing bowel-surgery due to the known impairments of intestinal motility. Opioids should only be used after the doctor has verified the normalisation of the bowel function.

Ixyldone consists of a polymer matrix and is intended for oral use only. In case of abusive parenteral venous injection, the tablet excipients (especially talc) may lead to serious, potentially fatal events.

The empty tablet matrix may be excreted visibly with the faeces.

The use of Ixyldone may lead to positive results for doping controls. Use of Ixyldone as a doping agent may become a health hazard.

This medicinal product contains lactose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose- isomaltase insufficiency should not take this medicine.

Opioid Use Disorder (abuse and dependence)

Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as oxycodone.

Repeated use of Ixyldone may lead to Opioid Use Disorder (OUD). A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of Ixyldone may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).

Before initiating treatment with Ixyldone and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behavior (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.

Hepatobiliary disorders

Ixyldone may cause dysfunction and spasm of the sphincter of Oddi, thus increasing the risk of biliary tract symptoms and pancreatitis. Therefore, oxycodone has to be administered with caution in patients with pancreatitis and diseases of the biliary tract.

4.5. Interaction with other medicinal products and other forms of interaction

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Drugs affecting the central nervous system (CNS) include other opioids, gabapentinoids such as pregabalin, anxiolytics, sedatives hypnotics (including benzodiazepines), antipsychotics, antidepressants, phenothiazines and alcohol.

Alcohol may enhance the pharmacodynamic effects of Ixyldone; concomitant use should be avoided.

Concomitant administration of oxycodone with serotonin agents, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) may cause serotonin toxicity. The symptoms of serotonin toxicity may include mental-status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). Oxycodone should be used with caution and the dosage may need to be reduced in patients using these medications.

Agents with anticholinergic activity (e.g. antipsychotics, tricyclic antidepressants, antihistamines, antiemetics, muscle relaxants, medicinal products against Morbus Parkinson) may result in increased anticholinergic adverse effects (e.g. constipation, dry mouth or dysfunction of urinary excretion).

Ixyldone should be used with caution in patients administered MAO-inhibitors or who have received MAO-inhibitors during the last two weeks.

A clinically relevant decrease or increase of INR (International Normalized Ratio) has been observed in individual cases in simultaneous use of oxycodone and coumarin anticoagulants.

Oxycodone is metabolised mainly by CYP3A4, with a contribution from CYP2D6. The activities of these metabolic pathways may be inhibited or induced by various co- administered drugs or dietary elements. The following sections explain these interactions in more detail.

CYP3A4 inhibitors, such as macrolide antibiotics (e.g. clarithromycin, erythromycin and telithromycin), azolantifungals (e.g. ketoconazole, voriconazole, itraconazole, and posaconazole), protease inhibitors (e.g. boceprevir, ritonavir, indinavir, nelfinavir and saquinavir), cimetidine and grapefruit juice may cause a reduced clearance of oxycodone that could cause an increase of the plasma concentrations of oxycodone. Therefore, the oxycodone dose may need to be adjusted accordingly.

Some specific examples of CYP3A4 enzyme inhibition are provided below:

• Itraconazole, a potent CYP3A4 inhibitor, administered 200 mg orally for five days, increased the AUC of oral oxycodone. On average, the AUC was approximately 2.4 times higher (range 1.5 - 3.4).

• Voriconazole, a CYP3A4 inhibitor, administered 200 mg twice-daily for four days (400 mg given as first two doses), increased the AUC of oral oxycodone. On average, the AUC was approximately 3.6 times higher (range 2.7 - 5.6).

• Telithromycin, a CYP3A4 inhibitor, administered 800 mg orally for four days, increased the AUC of oral oxycodone. On average, the AUC was approximately 1.8 times higher (range 1.3 - 2.3).

• Grapefruit Juice, a CYP3A4 inhibitor, administered as 200 ml three times a day for five days, increased the AUC of oral oxycodone. On average, the AUC was approximately 1.7 times higher (range 1.1 - 2.1).

CYP3A4 inducers, such as rifampicin, carbamazepine, phenytoin and St John´s Wort may induce the metabolism of oxycodone and cause an increased clearance of oxycodone that could cause a reduction of the plasma concentrations of oxycodone. The oxycodone dose may need to be adjusted accordingly. Some specific examples are provided below:

• St Johns Wort, a CYP3A4 inducer, administered as 300 mg three times a day for fifteen days, reduced the AUC of oral oxycodone. On average, the AUC was approximately 50% lower (range 37-57%).

• Rifampicin, a CYP3A4 inducer, administered as 600 mg once-daily for seven days, reduced the AUC of oral oxycodone. On average, the AUC was approximately 86% lower

Drugs that inhibit CYP2D6 activity, such as paroxetine and quinidine, may cause decreased clearance of oxycodone which could lead to an increase in oxycodone plasma concentrations.

Children and adolescents

Drug interaction studies have only been conducted in adults.

4.6. Fertility, pregnancy and lactation

Use of this medicinal product should be avoided to the extent possible in patients who are pregnant or lactating.

Pregnancy

There are limited data from the use of oxycodone in pregnant women. Infants born to mothers who have received opioids during the last 3 to 4 weeks before giving birth should be monitored for respiratory depression. Withdrawal symptoms may be observed in the newborn of mothers undergoing treatment with oxycodone.

Breast-feeding

Oxycodone may be excreted in breast milk and may cause sedation and respiratory depression in the breastfed child. Oxycodone should, therefore, not be used in breastfeeding mothers.

Fertility

No human data on the effect of oxycodone on fertility are available. Studies in rats have not shown any effects upon fertility (see section 5.3).

4.7. Effects on ability to drive and use machines

This medicine can impair the ability to drive and use machines. This is particularly likely at the beginning of the treatment with Oxycodone, after dose increase or change of product and if Oxycodone is combined with other CNS depressant agents.

With stable therapy, a general ban on driving a vehicle is not necessary.

The treating physician should decide on a case-by-case basis whether the patient is allowed to drive or operate machines.

This medicine can impair cognitive function and can affect a patient's ability to drive safely.

This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive

• Do not drive until you know how the medicine affects you

• It is an offence to drive while under the influence of this medicine

• However, you would not be committing an offence (called 'statutory defence') if:

o The medicine has been prescribed to treat a medical or dental problem and

o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and

o It was not affecting your ability to drive safely

Oxycodone may impair the ability to drive and use machines. This is particularly likely at the beginning of the treatment with Ixyldone, after dose increase or change of product and if Oxycodone is combined with other CNS depressant agents. With stable therapy, a general ban on driving a vehicle is not necessary. The treating physician should decide on a case-by-case basis whether the patient is allowed to drive or operate machines.

4.8. Undesirable effects

Due to its pharmacological properties, oxycodone can cause respiratory depression, miosis, bronchial spasms and spasms of the smooth muscles and can suppress the cough reflex.

The most frequently reported undesirable effects are nausea (especially at the beginning of the treatment) and obstipation.

The most serious adverse reaction, as with other opioids, is respiratory depression. This is most likely to occur in elderly, debilitated or opioid-intolerant patients.

In susceptible patients opioids may cause a severe drop in blood pressure.

The frequency of adverse reactions is based on the following categories:

Very common (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000),

Not known (cannot be estimated from the available data)

Very common

Common

Uncommon

Rare

Not known (cannot be estimated from available data)

Infections and infestations

Herpes simplex.

Immune system disorders:

Hypersensitivity reactions.

Anaphylactic reactions.

Anaphylactoid reaction.

Metabolism and nutrition disorders:

decreased appetite up to loss of appetite.

Dehydration.

Increase appetite

Psychiatric disorders:

Anxiety, confusional state, depression,decreased activity, restlessness, psychomotor hyperactivity, nervousness, insomnia, abnormal thinking.

Agitation, affect lability, euphoric mood, perception disorder (e.g. hallucinations, derealization), decreased libido, drug dependence (see section 4.4)

Aggression

Nervous system disorders:

Somnolence; sedation, dizziness; headache.

Tremor, lethargy.

Amnesia, convulsion (especially in patients with epilepsy or predisposition to convulsions), concentration impaired, migraine, hypertonia; involuntary muscle contractions, hypoaesthesia; abnormal coordination, speech disorder, syncope, paraesthesia, dysgeusia.

Hyperalgesia.

Eye disorders:

visual impairment; miosis

Ear and labyrinth disorders:

Hearing disorders, Vertigo.

Cardiac disorders:

tachycardia, palpitations (in context of withdrawal syndrome).

Vascular disorders:

Vasodilatation

Hypotension; orthostatic hypotension.

Respiratory, thoracic and mediastinal disorders:

Dyspnoea,

Respiratory depression; Dysphonia,

coughing

Central sleep apnoea syndrome

Gastrointestinal disorders:

Constipation; nausea; vomiting.

abdominal pain; diarrhoea; dry mouth, hiccups, dyspepsia.

Oral ulcers; stomatitis; flatulence; eructation; dysphagia; ileus.

Malaena, dental disease, tooth disorders, gingival bleeding

Dental caries.

Hepatobiliary disorders:

Increased hepatic enzymes.

Cholestasis; biliary colic. Sphincter of Oddi dysfuntion

Skin and subcutaneous tissue disorders:

Pruritus

Skin reaction/rash hyperhidrosis;

Dry skin.

urticaria.

Renal and urinary disorders:

Dysuria, Micturition urgency

Urinary retention.

Reproductive system and breast disorders:

Erectile dysfunction, Hypogonadism.

Amenorrhoea.

General disorders and administration site conditions:

Asthenic conditions, Fatigue.

Chills; withdrawal syndrome, pain (e.g. chest pain); malaise; oedema; peripheral oedema; drug tolerance; thirst.

Weight increase or decrease

Drug withdrawal syndrome in new-borns.

Injury, poisoning and complications

Injuries from accidents.

Children and adolescents

The frequency, nature and severity of adverse reactions in patients under 12 years of age are not expected to be different from those in adults and adolescents 12 years and over. For new borns, born to mothers receiving oxycodone, see section 4.6.

Drug dependence

Repeated use of Ixyldone can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Symptoms and intoxication:

Acute overdose with oxycodone may result in respiratory depression, somnolence, progressing up to stupor or coma, decreased skeletal muscle tone miosis, bradycardia and drop in blood pressure, pulmonary oedema, circulatory failure and death.

Toxic leukoencephalopathy has been observed with oxycodone overdose.

Therapy of intoxications:

The airways must be kept clear. Pure opioid antagonists such as naloxone are specific antidotes against symptoms of opioid overdose. Other supportive measures should be employed as needed.

Naloxone: e.g. 0.4-2 mg intravenous. Administration of single doses must be repeated depending on the clinical situation at intervals of 2 to 3 minutes. Intravenous infusion of 2 mg of naloxone in 500 ml isotonic saline or 5% dextrose solution (corresponding to 0.004 mg naloxone/ml) is possible. The rate of infusion should be adjusted to the previous bolus injections and the response of the patient.

Other supportive measures including artificial respiration, oxygen supply, administration of vasopressors and infusion therapy should be applied in the treatment of accompanying circulatory shock. Upon cardiac arrest or cardiac arrhythmias, cardiac massage or defibrillation may be indicated. Water and electrolyte balance should be maintained.

💬 Ask about this leaflet

Ask anything about Ixyldone 40 mg prolonged-release tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →